Amgen Selects Veeva Vault CRM for Global Rollout
Amgen chose Veeva Vault CRM for global use. The move supports Veeva's record CRM quarter and 180-plus live customers.
Key points
- Amgen selected Veeva Vault CRM for a global rollout, extending a partnership of over ten years.
- Veeva reported its best-ever CRM quarter with 13% year-over-year growth in commercial subscription revenue.
- The company has more than 180 live Vault CRM customers and targets over 70% market share in life sciences CRM.
Veeva Systems secured a global deployment of its Vault CRM platform by Amgen, extending a partnership that has spanned more than a decade. This expansion aligns with Veeva's recent report of its strongest-ever quarter for commercial subscription revenue, which grew 13% year over year.
The agreement positions Vault CRM as the central commercial foundation for Amgen’s worldwide therapy launches. As noted in reporting by TradingView, this deal reinforces Veeva’s strategy of deepening ties with large biopharma clients to drive long-term subscription growth.
Record CRM Revenue Drives Growth
Veeva management identified the fiscal second quarter of 2027 as its best CRM period to date. Commercial subscription revenue increased by approximately 13% year over year, supported by broad-based strength across CRM, content, data, and Crossix segments.
The company now serves over 180 live Vault CRM customers, including major enterprise deployments. Management maintains confidence in retaining more than 70% market share in the life sciences CRM sector, citing a shift toward integrated, AI-enabled platforms.
AI Features Enhance Field Operations
The platform supports an agentic commercial model that integrates workflows with AI-powered tools. Features like Agentic Call Report generate commercial evidence and help identify treatment barriers, allowing field teams to streamline interactions with healthcare professionals.
Amgen stated the migration will accelerate the delivery of new therapies with greater speed and agility. The deployment offers Veeva additional cross-sell opportunities across its broader commercial suite as customers seek unified solutions.
Market Context and Valuation
Veeva’s market capitalization stands at $42.13 billion. Year-to-date, the stock has gained 16.8%, outpacing the industry’s 13.5% growth and the S&P 500’s 11.4% rise during the same period.
Industry data from Grand View Research values the global healthcare CRM market at $21.5 billion in 2025. Projections indicate growth to $23.3 billion in 2026, reflecting sustained demand for modernized commercial operations in life sciences.
